Boissel J P
Département méthodologie et essais thérapeutiques, hôpital neuro-cardiologique, Lyon.
Arch Mal Coeur Vaiss. 1991 Nov;84(11 Suppl):1721-4.
Intermittent claudication has changed from being only a disabling symptom to being an indication for secondary prevention of coronary and cerebrovascular events. Epidemiological studies have shown claudication to be a risk factor of cardiac and cerebral morbidity and mortality and clinical trials have sought to show that some antiaggregant agents could reduce the risk and improve the prognosis. These objectives have practically been attained, in particular with ticlopidine. The reduction of cardiovascular and cerebral risk observed in the meta-analysis of clinical trials with aspirin has had a uniting role for the use of antiaggregant drugs in all spheres of atherosclerotic pathology.
间歇性跛行已从仅仅是一种致残症状转变为冠状动脉和脑血管事件二级预防的指征。流行病学研究表明，跛行是心脏和脑部发病及死亡的危险因素，临床试验试图证明某些抗血小板药物可降低风险并改善预后。这些目标实际上已经实现，尤其是噻氯匹定。阿司匹林临床试验的荟萃分析中观察到的心血管和脑血管风险降低，对在动脉粥样硬化病变的各个领域使用抗血小板药物起到了统一作用。
